Newswire (Published: Friday, June 7, 2019, Received: Friday, June 7, 2019, 6:50:08 PM CDT)
Word Count: 474
2019 JUN 07 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Daily -- Research findings on Oncology - Prostate Cancer are discussed in a new report. According to news reporting originating from Chicago, United States, by NewsRx correspondents, research stated, “Androgens are thought to cause prostate cancer, but the underlying mechanisms are unclear. Data from animal studies suggest that for androgens to cause prostate cancer, they must be aromatized to estrogen and act in concert with estrogen metabolites.”
Funders for this research include National Cancer Institute, Prevent Cancer Foundation.
Our news editors obtained a quote from the research from the University of Illinois - Chicago, “We tested the hypothesis that androgen-receptor and estrogen receptor-mediated effects of androgen and estrogen are necessary, as well as genotoxicity of estrogen metabolites. NBL rats were treated with androgenic and estrogenic compounds for 16-75 weeks through slow-release silastic implants or pellets. Testosterone alone induced cancer in the prostate of 37% of rats. 5a-Dihydrotestosterone, which cannot be converted to estradiol or testosterone, did not cause a significant prostate cancer incidence (4%). Addition of estradiol to 5a-dihydrotestosterone treatment did not markedly enhance prostate cancer incidence (14%), unlike adding estradiol to testosterone treatment which induced a 100% tumor incidence. Testosterone plus estradiol treatment induced a DNA adduct detectable by P-postlabeling, oxidative DNA damage (8-hydroxyguanosine), and lipid peroxidation at the site within the prostate where this treatment causes cancers, preceding later cancer formation. The non-estrogenic 4-hydroxy metabolite of estradiol, when combined with testosterone, induced prostatic dysplasia within 16 weeks and, after long-term treatment, a very low incidence of prostate cancer (21%). When an estrogen that cannot be hydroxylated (2-fluoroestradiol) was added to this combined treatment with testosterone and 4-hydroxyestradiol, dysplasia frequency after 16 weeks was doubled.”
According to the news editors, the research concluded: “These results strongly support the hypothesis, but additional definitive studies are needed which may identify new targets to interfere with these mechanisms that are clinically feasible in humans.”
For more information on this research see: Role of Estrogen in Androgen-Induced Prostate Carcinogenesis in NBL Rats. Hormones and Cancer, 2019;10(2-3):77-88. (Springer - www.springer.com; Hormones and Cancer - http://www.springerlink.com/content/1868-8497/)
The news editors report that additional information may be obtained by contacting M.C. Bosland, Dept. of Pathology, University of Illinois, Chicago, IL 60612, United States. Additional authors for this research include K. Vega, J. Liehr, X. Huang, L. Horton, E.L. Cavalieri, E.G. Rogan and M.C Bosland.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s12672-019-00360-7. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)
National Cancer Institute
Prevent Cancer Foundation
University of Illinois
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues